BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 9716055)

  • 1. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
    Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG;
    N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
    Schrama JG; Faneyte IF; Schornagel JH; Baars JW; Peterse JL; van de Vijver MJ; Dalesio O; van Tinteren H; Rutgers EJ; Richelt DJ; Rodenhuis S
    Ann Oncol; 2002 May; 13(5):689-98. PubMed ID: 12075736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
    Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
    Cancer; 1998 Sep; 83(5):936-47. PubMed ID: 9731898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
    Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
    Nitz UA; Mohrmann S; Fischer J; Lindemann W; Berdel WE; Jackisch C; Werner C; Ziske C; Kirchner H; Metzner B; Souchon R; Ruffert U; Schütt G; Pollmanns A; Schmoll HJ; Middecke C; Baltzer J; Schrader I; Wiebringhaus H; Ko Y; Rösel S; Schwenzer T; Wernet P; Hinke A; Bender HG; Frick M;
    Lancet; 2005 Dec; 366(9501):1935-44. PubMed ID: 16325695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
    Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 20. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
    Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
    Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.